The Carlyle Group’s Investment in TriNetX

Debevoise & Plimpton LLP advised The Carlyle Group on the deal.

The Carlyle Group (NASDAQ: CG) completed its investment in TriNetX, a leading global health research network optimizing clinical research to bring new therapies to market faster.

The Carlyle Group, which manages $221 billion of assets, is a global investment firm with deep industry expertise that deploys private capital across four business segments: corporate private equity, real assets, global credit and investment solutions.

TriNetX is a global health research network that connects the world of drug discovery and development from pharmaceutical company to study site, and investigator to patient by sharing real-world data to make clinical and observational research easier and more efficient.

SVB Leerink served as exclusive financial advisor to TriNetX.

The Debevoise team was led by M&A partners Jennifer Chu (Picture) and Kevin Rinker and included M&A counsel David Iozzi and associates Lauren Beasley, Victoria Jimenez, Ethan McMahon, Bradley Polivka and Sergio Torres, benefits partner Jon Lewis and associate Zain Kazmi, tax partner Peter Furci and associate Jay Evans and intellectual property partner Jeffrey Cunard and associate Melody Godbolt.

Involved fees earner: Lauren Beasley – Debevoise & Plimpton; Jennifer Chu – Debevoise & Plimpton; Jeffrey Cunard – Debevoise & Plimpton; Jay Evans – Debevoise & Plimpton; Peter Furci – Debevoise & Plimpton; Melody Godbolt – Debevoise & Plimpton; David Iozzi – Debevoise & Plimpton; Victoria Jimenez – Debevoise & Plimpton; Zain Kazmi – Debevoise & Plimpton; Ethan Lee McMahon – Debevoise & Plimpton; Jonathan Lewis – Debevoise & Plimpton; Kevin Rinker – Debevoise & Plimpton; Sergio Torres – Debevoise & Plimpton;

Law Firms: Debevoise & Plimpton;

Clients: The Carlyle Group;

Author: Ambrogio Visconti